The CARA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CARA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CARA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
![]() |
View CARA Detailed Price Forecast - CNN Money | ![]() |
View CARA Detailed Summary - Google Finance |
![]() |
View CARA Detailed Summary - Yahoo! Finance | ![]() |
View CARA Stock Research & Analysis - Zacks.com |
![]() |
View CARA Trends & Analysis - Trade-Ideas | ![]() |
View CARA Major Holders - Barrons |
![]() |
View CARA Call Transcripts - NASDAQ | ![]() |
View CARA Breaking News & Analysis - Seeking Alpha |
![]() |
View CARA Annual Report - CompanySpotlight.com | ![]() |
View CARA OTC Short Report - OTCShortReport.com |
![]() |
View CARA Fundamentals - TradeKing | ![]() |
View CARA SEC Filings - Bar Chart |
![]() |
View Historical Prices for CARA - The WSJ | ![]() |
View Performance/Total Return for CARA - Morningstar |
![]() |
View the Analyst Estimates for CARA - MarketWatch | ![]() |
View the Earnings History for CARA - CNBC |
![]() |
View the CARA Earnings - StockMarketWatch | ![]() |
View CARA Buy or Sell Recommendations - MacroAxis |
![]() |
View the CARA Bullish Patterns - American Bulls | ![]() |
View CARA Short Pain Metrics - ShortPainBot.com |
![]() |
View CARA Stock Mentions - StockTwits | ![]() |
View CARA Stock Mentions - PennyStockTweets |
![]() |
View CARA Stock Mentions - Twitter | ![]() |
View CARA Investment Forum News - Investor Hub |
![]() |
View CARA Stock Mentions - Yahoo! Message Board | ![]() |
View CARA Stock Mentions - Seeking Alpha |
![]() |
View Insider Transactions for CARA - SECform4.com | ![]() |
View Insider Transactions for CARA - Insider Cow |
![]() |
View CARA Major Holdings Summary - CNBC | ![]() |
View Insider Disclosure for CARA - OTC Markets |
![]() |
View Insider Transactions for CARA - Yahoo! Finance | ![]() |
View Institutional Holdings for CARA - NASDAQ |
![]() |
View CARA Stock Insight & Charts - FinViz.com | ![]() |
View CARA Investment Charts - StockCharts.com |
![]() |
View CARA Stock Overview & Charts - BarChart | ![]() |
View CARA User Generated Charts - Trading View |
Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript
Posted on Tuesday November 14, 2023
Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript November 13, 2023 Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0.5. Operator: Good afternoon. My name is Latif and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics Third Quarter Financial Results […]
Q3 2023 Cara Therapeutics Inc Earnings Call
Posted on Tuesday November 14, 2023
Q3 2023 Cara Therapeutics Inc Earnings Call
Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to Say
Posted on Monday November 13, 2023
The headline numbers for Cara (CARA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cara Therapeutics Reports Third Quarter 2023 Financial Results
Posted on Monday November 13, 2023
– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all three late-stage oral difelikefalin clinical programs anticipated within current financial runway – – Topline results from Part A of KIND 1 Phase 3 atopic dermatitis trial expected in December 2023 – – 3Q23 total revenue of $4.9M including collaborative revenue of $1.9M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – –